Cardinal Health — Feb 5, 2026 release

This updated guidance reflects: • Pharmaceutical and Specialty Solutions segment profit growth raised and narrowed to 20% to 22%, from the prior range of 16% to 19% • Global Medical Products and Distribution segment profit raised to approximately $150 million, from the prior guidance of at least $140 million • Other segment profit growth raised to 33% to 35%, from the prior range of 29% to 31% • Non-GAAP effective tax rate decreased to a range of 21% to 23%, from the prior range of 22% to 24% • Diluted weighted average shares outstanding decreased to a range of 237 million to 238 million, from the prior outlook of ~238 million Recent highlights • Cardinal Health completed an additional $375 million accelerated share repurchase program in the second quarter, bringing year-to-date share repurchases in fiscal year 2026 to $750 million. • Cardinal Health’s The Specialty Alliance leading multi-specialty MSO platform completed the acquisition of Solaris Health, the country’s leading Urology MSO with over 750 providers, on November 3 rd . • Cardinal Health’s direct-to-patient at-Home Solutions business recently introduced the ContinuCare™ Pathway program, which leverages the full Cardinal Health portfolio to simplify diabetes supply management for partner pharmacies and patients, and announced a key partnership with Publix Super Markets Inc. • Reinforcing its commitment to a world-class culture, Cardinal Health earned Great Place to Work Certification in six countries, including the U.S. Cardinal Health Page 4 Webcast Cardinal Health will host a webcast today at 8:30 a.m. ET to discuss second quarter results. To access the webcast and corresponding slide presentation, go to the Investor Relations page at ir.cardinalhealth.com . No access code is required. Presentation sl